PositoAI/ US/ Retension Pharmaceuticals, Inc.

Retension Pharmaceuticals, Inc.

NasdaqCM: RTSN · Healthcare

Positivity Index

#6,439 / 6,774

Global

#3,700 / 4,000

United States

Positivity Score

-19,555

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

Retension Pharmaceuticals, Inc. — Overview & Financial Snapshot

Retension Pharmaceuticals, Inc. (NasdaqCM: RTSN) is a Healthcare company, ranked #6,439 of 6,774 companies globally and #3,700 of 4,000 in United States on PositoAI, with a Positivity Score of -19,555. Its market capitalisation is ₹1,218.96 Cr ($129.14M), P/E ratio is -5.9 and P/B ratio is -0.84. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#3 Dogwood Therapeutics, Inc. 27,827 #8 Impact BioMedical Inc. 26,149 #13 Onconetix, Inc. 25,902 #15 Revelation Biosciences, Inc. 25,780 #18 Vyome Holdings, Inc. 25,696

— Nothing to show —

OpenAI is reading recent news...

Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The Company operates as a single operating and reportable segment focused on the development of treatments for hypertension and cardiovascular disease. The company was incorporated in 2023 and is headquartered in Falls Church, Virginia.

P/B Ratio -0.84

P/E Ratio -5.9

D/E Ratio 0.00

ROE —

Owes vs Owns ? —Not available

Dividend Yield 0.00%

Trailing EPS ₹-246.36$-2.61

Forward EPS —

Beta —

Market Cap ₹1,218.96 Cr$129.14M

What these numbers mean →

What does Retension Pharmaceuticals, Inc. do?

What is Retension Pharmaceuticals, Inc.'s P/E and P/B ratio?

Retension Pharmaceuticals, Inc. has a P/E ratio of -5.9 and a P/B ratio of -0.84.

What is Retension Pharmaceuticals, Inc.'s debt-to-equity ratio?

Retension Pharmaceuticals, Inc. has a debt-to-equity ratio of 0.00.

What is Retension Pharmaceuticals, Inc.'s Positivity rank?

Retension Pharmaceuticals, Inc. is ranked #6,439 of 6,774 companies globally and #3,700 of 4,000 in United States on PositoAI, with a Positivity Score of -19,555.

Does Retension Pharmaceuticals, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Retension Pharmaceuticals, Inc..

Where can I read the latest news about Retension Pharmaceuticals, Inc.?

Recent headlines about Retension Pharmaceuticals, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Retension Pharmaceuticals, Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Retension Pharmaceuticals, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.